Effects of mAChR subtype-selective antagonists on IKTMA, IK4AP, and IKACh
| Pirenzepine, 10 nM | Methoctramine, 20 nM | 4-DAMP, 2 nM | Tropicamide, 200 nM | ||
|---|---|---|---|---|---|
| pA/pF | |||||
| IKTMA | |||||
| +50 mV | Control | 13.9 ± 2.1 | 12.7 ± 2.7 | 11.5 ± 0.6 | 9.0 ± 1.1 |
| Drug | 14.0 ± 2.0 | 12.2 ± 2.7 | 6.4 ± 0.4** | 9.1 ± 1.2 | |
| % change | 1.0 ± 3.5 | −4.0 ± 0.6 | −42.8 ± 6.1 | 0.5 ± 1.7 | |
| −100 mV | Control | 4.2 ± 0.9 | 4.1 ± 1.0 | 2.2 ± 0.3 | 3.5 ± 0.8 |
| Drug | 4.3 ± 0.5 | 4.2 ± 0.9 | 1.1 ± 0.2** | 3.8 ± 1.0 | |
| % change | 5.8 ± 8.2 | 3.1 ± 4.0 | −50.9 ± 5.1 | 5.2 ± 7.4 | |
| (n = 4) | (n = 5) | (n = 6) | (n = 4) | ||
| IK4AP | |||||
| +50 mV | Control | 6.8 ± 1.5 | 7.8 ± 0.9 | 8.7 ± 0.2 | 7.1 ± 1.0 |
| Drug | 6.9 ± 1.6 | 8.0 ± 0.8 | 9.0 ± 0.5 | 3.8 ± 0.5** | |
| % change | 1.5 ± 3.8 | −3.7 ± 0.9 | 7.2 ± 3.4 | −46.4 ± 3.1 | |
| −100 mV | Control | 3.8 ± 1.1 | 3.4 ± 1.0 | 3.8 ± 1.5 | 2.7 ± 0.3 |
| Drug | 4.1 ± 1.2 | 3.8 ± 1.6 | 3.7 ± 1.3 | 1.6 ± 0.2*** | |
| % change | 5.9 ± 3.0 | 12.9 ± 4.4 | −0.7 ± 5.1 | −41.8 ± 4.5 | |
| (n = 3) | (n = 3) | (n = 4) | (n = 5) | ||
| IKACh | |||||
| +50 mV | Control | 7.0 ± 1.0 | 6.4 ± 0.6 | 5.9 ± 0.9 | 6.2 ± 0.5 |
| Drug | 6.9 ± 1.2 | 9.4 ± 1.0** | 5.7 ± 0.5 | 6.1 ± 0.3 | |
| % change | −0.2 ± 0.3 | 44.8 ± 4.0 | −3.4 ± 0.5 | −1.6 ± 1.0 | |
| −100 mV | Control | 11.2 ± 3.0 | 9.4 ± 2.1 | 10.4 ± 1.3 | 9.1 ± 1.8 |
| Drug | 10.9 ± 4.1 | 14.8 ± 1.1 | 9.8 ± 3.5 | 8.9 ± 2.1 | |
| % change | −1.0 ± 0.4 | −57.4 ± 4.7*** | −5.2 ± 1.2 | −2.2 ± 2.2 | |
| (n = 3) | (n = 6) | (n = 3) | (n = 3) |
1-150 p < .05, ** p < .01, *** p < .001. Student’s t test, compared with control.